<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079715</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT Number 2010-018737-21</org_study_id>
    <nct_id>NCT01079715</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity</brief_title>
  <acronym>PROP-ROP</acronym>
  <official_title>Safety and Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Meyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Meyer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of propranolol is
      effective in the treatment of the retinopathy of the prematurity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinopathy of Prematurity (ROP) is still a major cause of blindness in children in developed
      countries around the world, and an increasing cause of blindness in developing countries. The
      ablation of the retina with photocoagulation by laser or cryotherapy reduces the incidence of
      blindness by suppressing the neovascular phase of ROP. However, the visual outcomes after
      treatment are often poor. The development of ROP depends largely from vascular endothelial
      growth factor (VEGF). The reduction of VEGF expression in the neovascular phase might prevent
      destructive neovascularization in ROP.

      The purpose of this study is to evaluate whether the administration of propranolol is safe
      and is able to reduce the incidence of blindness by suppressing the neovascular phase of ROP
      compared to a control group receiving conventional laser therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary aim is to evaluate the safety of propranolol administration</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary aim is to evaluate the efficacy of treatment with propranolol for reducing blindness and retinal detachment in newborns with ROP</measure>
    <time_frame>six months from the beginning of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Propranolol administration is the experimental arm of this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).
In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.
In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.
In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:
Atropine.
Isoproterenol hydrochloride (isoprenaline.
Terlipressin.
Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants who have been screened for ROP (≤ 32 weeks gestation) who develop Stage 2 ROP
             in zone II without plus.

          2. Informed Consent from a parent

        Exclusion Criteria:

          1. Newborns with one or more of the following conditions at the enrollment in the study:

               -  Heart failure.

               -  Recurrent episodes of bradycardia (Heart rate less than 90 bpm).

               -  Atrio-ventricular block (second or third degree).

               -  Significant congenital heart anomaly, not including patent ductus arteriosus,
                  patent foramen ovale or small ventricular septal defect.

               -  Hypotension.

               -  Renal failure.

               -  Cerebral hemorrhage.

               -  Other diseases which contraindicate the use of beta-blockers

          2. Newborns with ROP stages more advances than Stage 2 in zone II without plus.

          3. Informed Consent from a parent refused. This will mean that an infant automatically
             will receive standard laser therapy. No data will be used from an infant without
             Informed Consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Filippi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria A. Meyer, Firenze, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit - Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>I-50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit - Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>I-20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/</url>
    <description>Drug information</description>
  </link>
  <reference>
    <citation>Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G, Araimo G, Ramenghi L, La Torre A, Fortunato P, Pollazzi L, la Marca G, Malvagia S, Bagnoli P, Ristori C, Dal Monte M, Bilia AR, Isacchi B, Furlanetto S, Tinelli F, Cioni G, Donzelli G, Osnaghi S, Mosca F. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010 Nov 18;10:83. doi: 10.1186/1471-2431-10-83.</citation>
    <PMID>21087499</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>November 24, 2012</last_update_submitted>
  <last_update_submitted_qc>November 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Meyer</investigator_affiliation>
    <investigator_full_name>Luca Filippi</investigator_full_name>
    <investigator_title>Dr. Luca Filippi</investigator_title>
  </responsible_party>
  <keyword>Newborn</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Angiogenesis Modulating Agents</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Angiogenesis Modulating Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

